Ichinosuke Hyodo

3PUBLICATIONS
48CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (3)

|May 16, 2025
Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High Advanced Gastric or Esophagogastric Junction Cancer.

Hisato Kawakami, Shigenori Kadowaki, Akitaka Makiyama

|Oct 25, 2024
Gut microbiome associated with PARP inhibitor efficacy in patients with ovarian cancer.

Mika Okazawa-Sakai, Shunsuke A Sakai, Ichinosuke Hyodo

Pageof 1